In 2008, Allon will release results from three Phase II human efficacy trials targeting three of these diseases: Alzheimer's disease, ischemic stroke and cognitive impairment associated with schizophrenia.

Positive results would establish AL-108 and AL-208 as the first drugs in development to impact a patient’s cognition by targeting the mechanisms that lead to physical damage in the brain.

Alzheimer’s disease

The first drug to treat Alzheimer’s disease came out in 1993. Since then, drugs have been developed that offer some symptomatic relief, but have no impact on the disease process itself or its progression.
(Source: Paul Aisen, MD. Director, the Alzheimer’s Disease Cooperative Study, U.S. National Institutes of Health. Professor, School of Medicine, Department of Neurosciences, University of California, San Diego.)

"If Allon's drug AL-108 can achieve in people what it achieved in animals, AL-108 will have demonstrated significant potential to become the first drug to treat the causes and halt the progression of Alzheimer's disease."

(Donald Schmechel, MD. Adjunct Professor of Medicine (Geriatics), Duke University Medical Center, Durham, North Carolina. Medical Director, The Falls Neurological and Memory Center, Caldwell Memorial Hospital, Lenoir, North Carolina.)